Life Science Case Studies

Prioritizing Molecule Strategy Opportunities
A mid-sized biotech company had more development opportunities than available funding. The company’s most pressing issue was centered on a molecule that had six ongoing clinical programs and three in draft protocol stage. The company needed help with prioritizing opportunities and determining which indications should be developed internally vs. preparing for an out-licensing strategy. The molecule’s potential covered a broad range of diseases including oncology, infectious diseases, and fibrotic diseases.

Applied Strategies helped the client establish a consistent and transparent methodology for valuing the risk and return of all the potential indications. Working with client project teams, as well as middle and senior management groups across all functions, we helped the client define development plan options, develop detailed timelines, and evaluate the risk and potential return of each indication. These analyses generated insights about the current and future competitive environment, competitor dynamics, and the potential for off-label use. These analyses enabled the client to maximize the value of this versatile molecule and better prioritize its projects going forward.

<< back